SILENCE THERAPEUTICS ORD 5P news, videos and press releases - Page 3
For more news please use our advanced search feature.
SILENCE THERAPEUTICS ORD 5P - More news...
SILENCE THERAPEUTICS ORD 5P - More news...
- Silence Therapeutics Reports Full-year 2020 Results
- Silence Therapeutics to Present at the Barclays Global Healthcare Conference
- Silence Therapeutics and Mallinckrodt Initiate Work on Third Target as Part of Ongoing RNAi Research Collaboration for Complement-Mediated Diseases
- Silence Therapeutics to Participate in March Investor Conferences
- Silence Therapeutics to Present at the 2021 SVB Leerink Global Healthcare Conference
- Silence Therapeutics Initiates Dosing in Phase 1 Clinical Trial of SLN360 for Cardiovascular Disease Due to High Lipoprotein(a)
- Silence Therapeutics plc Announces $45 Million Private Placement
- Silence Therapeutics Appoints Michael H. Davidson, MD, to Board of Directors
- Silence Therapeutics Appoints Craig Tooman as Chief Financial Officer
- Silence Therapeutics to Participate in January Virtual U.S. Investor Conferences
- Silence Therapeutics Presents Positive Pre-Clinical Data for SLN360 for the Treatment of Elevated Lipoprotein(a) at American Heart Association 2020
- Silence Therapeutics Appoints Dr. Marie Wikström Lindholm to its Executive Leadership Team
- Silence Therapeutics Announces Change to Executive Leadership Team
- Silence Therapeutics to Participate in the Chardan Virtual 4th Annual Genetic Medicines Conference
- Edison Investment Research Limited: Edison issues update on Silence Therapeutics (SLN)
- Edison Issues Update On Silence Therapeutics (SLN)
- Edison Investment Research Limited: Edison issues update on Silence Therapeutics (SLN)
- Edison issues update on Silence Therapeutics (SLN)
- Edison Investment Research Limited: Edison issues initiation on Silence Therapeutics (SLN)
- Edison Issues Initiation On Silence Therapeutics (SLN)
- Silence Therapeutics Notice of results and R&D day
-
Executive interview – Silence Therapeutics
- Mallinckrodt To Make An Equity Investment In Silence Therapeutics As Part Of A Collaboration To Develop And Commercialize RNAi Therapeutics For Complement-Mediated Diseases
- SILENCE THERAPEUTICS AND MALLINCKRODT ANNOUNCE COLLABORATION TO DEVELOP AND COMMERCIALIZE RNAi THERAPEUTICS FOR COMPLEMENT-MEDIATED DISEASES
- Mallinckrodt And Silence Therapeutics Announce Collaboration To Develop And Commercialize RNAi Therapeutics For Complement-Mediated Diseases
- SLN124 granted Orphan Drug Designation by EMA for the treatment of β-Thalassemia
- Silence Therapeutics advances next RNAi medicine
- US Patent Trial & Appeal Board (PTAB) Upholds Silence Patent by Denying First of Five Patent Grant Review Applications Filed by Alnylam
- Silence Therapeutics Announces Receipt of a New European Notice of Intention to Grant a Patent and the Launch of an Interim European Injunction Application against Onpattro™
-
Silence Therapeutics